Comparative Pharmacology
Head-to-head clinical analysis: ADVIL MIGRAINE LIQUI GELS versus EC NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL MIGRAINE LIQUI GELS versus EC NAPROSYN.
ADVIL MIGRAINE LIQUI-GELS vs EC-NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in pain, inflammation, and fever.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
400 mg (two 200 mg Liqui-Gels) orally every 6 to 8 hours as needed; maximum 1200 mg per day.
500-1000 mg orally twice daily; maximum 1500 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.8–3.5 hours). In clinical context, this short half-life supports dosing every 4–6 hours for acute migraine treatment, but drug effects may persist beyond this due to slow dissociation from COX enzymes.
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Renal excretion of unchanged drug and metabolites accounts for approximately 90% of an administered dose, with about 10% excreted in feces via bile. Less than 1% is excreted unchanged in urine; the remainder as conjugates and oxidative metabolites.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Category C
Category C
NSAID
NSAID